Side effects of Ozempic allegedly caused hospitalization, permanent injuries and other severe gastrointestinal complications, lawsuit claims.
The extensive pretrial proceedings mean the first Ozempic bellwether trials are unlikely to begin until at least 2026 or 2027.
Following the publication of recent studies, Danish health experts warn that they have received 19 reports of vision problems from Ozempic or Wegovy since July.
Findings are similar to those discovered by Harvard researchers in an Ozempic vision loss study published last summer.
With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.
Lawsuit claims Novo Nordisk's failures to warn about the risk of gastroparesis and Ileus from Ozempic were "wanton, willful, fraudulent, reckless acts."
The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
Amid increasing popularity of Ozempic, Wegovy and other GLP-1 drugs, researchers indicate that fewer patients are considering weight loss surgery.
New GLP-1 warnings will urge users to inform their doctors before surgery if they are taking the diabetes and weight loss drugs.
Court will examine general causation, along with other “cross cutting” issues, before selecting any individual Ozempic gastroparesis lawsuits for trial workup.
